Table 3

Deterministic results per patient of the base case and scenario analyses in a cohort of 1000 patients with cancer (2019, euros)

CostsQALYsΔCostsΔQALYsICER
Base case analysis: 5-year time horizon from societal perspective
 Rivaroxaban€31392.459−€14760.012Rivaroxaban dominant
 Dalteparin€46152.448
Scenario 1: 6-month time horizon from societal perspective
 Rivaroxaban€13610.304−€13120.004Rivaroxaban dominant
 Dalteparin€26730.300
Scenario 2: base case analysis from healthcare payer’s perspective
 Rivaroxaban€29422.459−€14960.012Rivaroxaban dominant
 Dalteparin€44382.448
Scenario 3: base case analysis with dalteparin dose of 12 500 IU
 Rivaroxaban€31392.459−€10790.012Rivaroxaban dominant
 Dalteparin€42182.448
Scenario 4: base case analysis with dalteparin dose of 18 000 IU
 Rivaroxaban€31392.459−€18980.012Rivaroxaban dominant
 Dalteparin€50372.448
Scenario 5: scenario one with treatment duration based on Streiff et al17
 Rivaroxaban€12990.289−€7020.016Rivaroxaban dominant
 Dalteparin€20010.273
Scenario 6: base case analysis using drug-specific distributions for the types of VTE and MB
 Rivaroxaban€30652.463−€18150.037Rivaroxaban dominant
 Dalteparin€48802.425
  • ICER, incremental cost-effectiveness ratio; IU, international units; MB, major bleeding; QALY, quality adjusted life-years; VTE, venous thromboembolism.